Lilly says Mounjaro and Zepbound contributed to big revenue boost
Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker’s stock rose 1.7% in premarket trading after it ...
Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...
Pros and cons of weight-loss jabs
Weight-loss jabs, such as Ozempic, Wegovy and Mounjaro, have quickly earned a glowing global reputation for shifting the ...
Gillingham charity boss hails weight-loss injections including Ozempic, Wegovy and Mounjaro as life-changing after dropping 6st in two months
A charity boss who struggled for years to shed pounds despite having undergone surgery has hailed weight-loss jabs as ...